scispace - formally typeset
Y

Yaron Vinik

Researcher at Weizmann Institute of Science

Publications -  21
Citations -  311

Yaron Vinik is an academic researcher from Weizmann Institute of Science. The author has contributed to research in topics: Galectin & Triple-negative breast cancer. The author has an hindex of 8, co-authored 20 publications receiving 177 citations.

Papers
More filters
Journal ArticleDOI

Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis

TL;DR: Ferroptosis was induced at low drug doses and was associated with increased cellular iron and decreased glutathione levels, concomitant with reduced levels of GPX4 and key glutathion biosynthesis genes.
Journal ArticleDOI

Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response.

TL;DR: A relatively low-cost, fast, and reliable method to isolate sEVs from plasma of BC patients and analyze their protein content by semiquantitative proteomics revealed a signature of seven proteins that differentiated BC patients from healthy individuals, of which FAK and fibronectin displayed high diagnostic accuracy.
Journal ArticleDOI

The mammalian lectin galectin-8 induces RANKL expression, osteoclastogenesis, and bone mass reduction in mice

TL;DR: These findings identify galectins as new players in osteoclastogenesis and bone remodeling, and highlight a potential regulation of bone mass by animal lectins.

FOR PEER REVIEW - CONFIDENTIAL The mammalian lectin galectin-8 induces RANKL expression, osteoclastogenesis and bone mass reduction in mice

TL;DR: Vinik et al. as discussed by the authors showed that mice overexpressing galectin-8, a secreted mammalian lectin of the galectins family, exhibit accelerated osteoclasts activity and bone turnover, which culminates in reduced bone mass, similar to cases of postmenopausal osteoporosis and cancerous osteolysis.
Journal ArticleDOI

Otubain 2 is a novel promoter of beta cell survival as revealed by siRNA high-throughput screens of human pancreatic islets

TL;DR: Use of dispersed human islets provides a new platform for functional HTS in a highly physiological system and identifies new targets, such as OTUB2, for therapeutic intervention in type 1 diabetes and islet transplantation.